The safety of vaccines plays a crucial role in fostering social stability and public trust.
We are developing a comprehensive quality management system that covers R&D, manufacturing, and distribution. This system imposes rigorous requirements on all personnel and facilities involved, including suppliers, laboratories, manufacturing facilities, and production workshops. Our commitment is to ensure top-notch vaccine quality from the outset, minimizing safety risks and providing the public with reliable immune protection.
Vaccine production facilities compliant with international quality standards.
Our quality management is certified for GMP by China, the European Union, and WHO.
We have constructed large-scale modernized vaccine manufacturing bases in Tianjin and Shanghai in China, with over 200,000 square meters.
In Tianjin, we have a campus of nearly 130,000 square meters. Built with a total investment of nearly RMB 10 billion, it is able to produce 280 million doses of vaccines a year on the existing production lines.?In Shanghai, we are building a facility for our mRNA vaccine at the Life Blue Bay Industrial Park of the Lin-gang Special Area. This facility will probe into the key technologies for the production of mRNA vaccines. The investment in Phase Ⅰ is over RMB 1 billion, and the plan is to build a facility of about 17,000 square meters.
CanSinoBIO Shanghai is pivotal to the company’s strategy for leading industrial upgrading, firmly positioning mRNA technology as the driving force behind our innovative R&D efforts.
CanSinoBIO Shanghai is the company's new R&D, production, business, and shareholding center. Revolving around the mRNA technology platform, this facility conducts early studies, process development, pilot production and scale-up, clinical and commercial drug scale production, international cooperation, etc. for preventive and therapeutic vaccines.
We leverage vaccine technology to reach across the globe and assist numerous nations in setting up localized production facilities, showcasing our exceptional capacity to combat the pandemic.
We helped Pakistan, Mexico, Malaysia, and other developing countries establish local filling lines through technology transfer, realize the local production of our COVID-19 vaccine, and expand the joint production of the vaccine. This demonstrates our commitment to developing global public health and equality.
津公網安備12011602300399
